Mobile

A trial to evaluate MLN0264 for the treatment of tumors of the stomach or the junction between the esophagus and the stomach and which have a protein called Guanylyl Cyclase C (GCC) present, in patien...

Mise à jour : Il y a 4 ans
Référence : U1111-1155-9023

A trial to evaluate MLN0264 for the treatment of tumors of the stomach or the junction between the esophagus and the stomach and which have a protein called Guanylyl Cyclase C (GCC) present, in patients that have been treated previously but who have relapsed or in whom the cancer has spread

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the overall response rate of patients with recurrent or metastatic GCC-positive adenocarcinoma of the stomach or gastroesophageal junction treated with MLN0264

Critère d'inclusion

  • Metastatic or Recurrent Adenocarcinoma of the Stomach or Gastroesophageal Junction Expressing Guanylyl Cyclase C (GCC)

Liens